DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas ; volume:23 ; number:1 ; day:6 ; month:5 ; year:2023 ; pages:1-14 ; date:12.2023
BMC neurology ; 23, Heft 1 (6.5.2023), 1-14, 12.2023
- Creator
-
Han, Myung-Hoon
Baek, Jeong Min
Min, Kyueng-Whan
Cheong, Jin Hwan
Ryu, Je Il
Won, Yu Deok
Kwon, Mi Jung
Koh, Seong-Ho
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-023-03236-0
- URN
-
urn:nbn:de:101:1-2023090610383657262690
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Han, Myung-Hoon
- Baek, Jeong Min
- Min, Kyueng-Whan
- Cheong, Jin Hwan
- Ryu, Je Il
- Won, Yu Deok
- Kwon, Mi Jung
- Koh, Seong-Ho
- SpringerLink (Online service)
Other Objects (12)
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach
STING cg16983159 methylation: a key factor for glioblastoma immunosuppression
CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
Immunosuppression
Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas
Chemical immunosuppression
Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas
High metallothionein predicts poor survival in glioblastoma multiforme
Radiotherapy for glioblastoma patients with poor performance status
Membrane Hsp70 expression in gliomas : a novel, hypoxia-related marker for primary glioblastoma
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach
STING cg16983159 methylation: a key factor for glioblastoma immunosuppression
CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
Immunosuppression
Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas
Chemical immunosuppression
Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas
High metallothionein predicts poor survival in glioblastoma multiforme
Radiotherapy for glioblastoma patients with poor performance status
Membrane Hsp70 expression in gliomas : a novel, hypoxia-related marker for primary glioblastoma
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach
STING cg16983159 methylation: a key factor for glioblastoma immunosuppression
CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
Immunosuppression
Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas
Chemical immunosuppression
Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas
High metallothionein predicts poor survival in glioblastoma multiforme
Radiotherapy for glioblastoma patients with poor performance status